Edward J. Bastyr

2.6k citations

27 papers · 1.9k indexed · h-index 22

Endocrinology, Diabetes and Metabolism top 1%
Physiology top 5%
Surgery top 10%
Molecular Biology
Neurology top 5%

Co-authors: Karen Price Vera Bril Aaron I. Vinik Louis Vignati CA Stuart Anthony J. Zagar Kenneth E. Robertson Sherwyn Schwartz
Topics: Diabetes Management and Research (14 papers)Diabetes Treatment and Management (13 papers)Pain Mechanisms and Treatments (6 papers)
Cited by: Endocrinology, Diabetes and Metabolism Neurology Physiology
Journals: Diabetes Care Cell Metabolism Muscle & Nerve
Partner nations: United States France United Kingdom

In The Last Decade

Edward J. Bastyr

27 papers receiving 1.8k citations

Peers

Countries citing papers authored by Edward J. Bastyr

Since Specialization

Citations

This map shows the geographic impact of Edward J. Bastyr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward J. Bastyr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward J. Bastyr more than expected).

Fields of papers citing papers by Edward J. Bastyr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward J. Bastyr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward J. Bastyr. The network helps show where Edward J. Bastyr may publish in the future.

Co-authorship network of co-authors of Edward J. Bastyr

This figure shows the co-authorship network connecting the top 25 collaborators of Edward J. Bastyr. A scholar is included among the top collaborators of Edward J. Bastyr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward J. Bastyr. Edward J. Bastyr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes 2017 ·Cell Metabolism ·Juan P. Frías,Edward J. Bastyr,Louis Vignati,Matthias H. Tschöp,Christophe Schmitt,(unknown),Rune Haubo Bojesen Christensen,Richard D. DiMarchi	257
2	The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro 2017 ·The Pharmacogenomics Journal ·Sreekumar Pillai,Suman Duvvuru,Pallav Bhatnagar,(unknown),Mark W. Farmen,Sudha S. Shankar,Cynthia J. Harris,Edward J. Bastyr,Byron J. Hoogwerf,Axel Haupt	13
3	Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins 2017 ·Journal of Investigative Medicine ·Arun J. Sanyal,Kenneth Cusi,Mark L. Hartman,Shuyu Zhang,Edward J. Bastyr,Juliana Bue‐Valleskey,Annette M. Chang,Axel Haupt,Scott J. Jacober,Robert J. Konrad,Qianyi Zhang,Byron J. Hoogwerf	2
4	Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3 2016 ·Diabetes Obesity and Metabolism ·Richard M. Bergenstal,Helen Lunt,Edward Franek,F. Travert,(unknown),Yongming Qu,Caryl J. Antalis,Mark L. Hartman,Myriam Rosilio,Scott J. Jacober,Edward J. Bastyr,(unknown)	40
5	Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes 2016 ·Diabetes Obesity and Metabolism ·Kenneth Cusi,Arun J. Sanyal,(unknown),Byron J. Hoogwerf,Annette M. Chang,Scott J. Jacober,(unknown),(unknown),Edward J. Bastyr,Axel Haupt,Mark L. Hartman	31
6	Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials 2016 ·Diabetes Obesity and Metabolism ·Henry N. Ginsberg,Bertrand Cariou,Trevor J. Orchard,Lei Chen,Junxiang Luo,Edward J. Bastyr,Juliana Bue‐Valleskey,Annette M. Chang,T. Iványi,Scott J. Jacober,Byron J. Hoogwerf	18
7	A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1 2016 ·Diabetes Obesity and Metabolism ·Satish K. Garg,M. Dreyer,Hideaki Jinnouchi,(unknown),Yongming Qu,Mark L. Hartman,Myriam Rosilio,Scott J. Jacober,Edward J. Bastyr,(unknown)	25
8	Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4 2016 ·Diabetes Obesity and Metabolism ·Thomas Blevins,Thomas R. Pieber,(unknown),(unknown),Edward J. Bastyr,Annette M. Chang,(unknown)	40
9	Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical Trials 2015 ·Diabetes Technology & Therapeutics ·Edward J. Bastyr,Shuyu Zhang,(unknown),(unknown),Stephen A. Raymond,Annette M. Chang	21
10	The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study 2011 ·Diabetes Obesity and Metabolism ·Guillermo E. Umpierrez,Thomas Blevins,Julio Rosenstock,(unknown),James H. Anderson,Edward J. Bastyr,(unknown)	74
11	A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-β Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral Neuropathy 2007 ·Diabetes Care ·Carolina Casellini,(unknown),(unknown),(unknown),Kathryn Simmons,Gary L. Pittenger,Edward J. Bastyr,Anne M. Wolka,Aaron I. Vinik	98
12	Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom 2007 ·Primary care diabetes ·Annalisa Rubino,Matthew D. Rousculp,(unknown),Jianmin Wang,Edward J. Bastyr,Solomon Tesfaye	28
13	Challenges in Design of Multicenter Trials 2007 ·Diabetes Care ·P. James B. Dyck,Jane E. Norell,Hans Tritschler,(unknown),Р. Р. Самигуллин,Dan Ziegler,Edward J. Bastyr,William J. Litchy,Peter C. O’Brien	92
14	Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials 2007 ·Diabetes Care ·Solomon Tesfaye,Rup Tandan,Edward J. Bastyr,Keri A. Kles,Vladimir Skljarevski,Karen Price,(unknown)	44
15	Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial 2005 ·Clinical Therapeutics ·Aaron I. Vinik,Vera Bril,Péter Kempler,William J. Litchy,Solomon Tesfaye,Karen Price,Edward J. Bastyr	116
16	Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy 2005 ·Clinical Therapeutics ·Edward J. Bastyr,Karen Price,Vera Bril	158
17	Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy 2005 ·Muscle & Nerve ·Aaron I. Vinik,Vera Bril,William J. Litchy,Karen Price,Edward J. Bastyr,(unknown)	45
18	The Development and Validation of the Norfolk QOL-DN, a New Measure of Patients' Perception of the Effects of Diabetes and Diabetic Neuropathy 2005 ·Diabetes Technology & Therapeutics ·Etta J. Vinik,Risa P. Hayes,Alan Oglesby,Edward J. Bastyr,(unknown),(unknown),Aaron I. Vinik	159
19	Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro 2000 ·Diabetes Obesity and Metabolism ·Edward J. Bastyr,Yijian Huang,Rocco L. Brunelle,Louis Vignati,Daniel J. Cox,James G. Kotsanos	23
20	Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure 1999 ·Clinical Therapeutics ·Edward J. Bastyr,Martin Johnson,Michael Trautmann,James H. Anderson,Louis Vignati	43

About Edward J. Bastyr

Edward J. Bastyr is a scholar working on Endocrinology, Diabetes and Metabolism, Neurology and Physiology, having authored 27 papers that have together received 1.9k indexed citations. Recurring topics across this work include Diabetes Management and Research (14 papers), Diabetes Treatment and Management (13 papers) and Pain Mechanisms and Treatments (6 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.1k citations), Neurology (360 citations) and Physiology (576 citations). Edward J. Bastyr has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Karen Price, Vera Bril, Aaron I. Vinik, Louis Vignati, CA Stuart, Anthony J. Zagar, Kenneth E. Robertson, Sherwyn Schwartz, Robert G. Brodows and William J. Litchy. Their work appears in journals such as Diabetes Care, Cell Metabolism and Muscle & Nerve.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact